Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Hexamine Hippurate
2. Hip-rex
3. Hiprex
4. Urex
5. Urotractan
1. 5714-73-8
2. Hiprex
3. Hexamine Hippurate
4. Hexamethylenetetramine Monohippurate
5. Hexamethylenetetramine Hippurate
6. 1,3,5,7-tetraazaadamantane Benzoylglycinate
7. Methenamine (hippurate)
8. Hippramine
9. Haiprex
10. Viapta
11. 2-benzamidoacetic Acid;1,3,5,7-tetrazatricyclo[3.3.1.13,7]decane
12. M329791l57
13. Glycine, N-benzoyl, Compd. With 1,3,5,7-tetraazatricyclo(3.3.1.1(sup 3,7))decane (1:1)
14. Hexamethylenetetramine Monohippurate;hexamethylenetetramine Monohippurate
15. Methenamine Hippurate [usan]
16. R-657
17. Einecs 227-206-5
18. Hexamethylene Tetramine Hippurate
19. Unii-m329791l57
20. Hiprex (tn)
21. Urex (tn)
22. Hippuric Acid, Compd. With Hexamethylenetetramine (1:1)
23. Methenamine Hippurate [usan:usp:inn:ban]
24. Schembl3029
25. Chebi:6825
26. Chembl1201104
27. Dtxsid10972603
28. Methenamine Hippurate (jan/usp)
29. Methenamine Hippurate [jan]
30. Hy-b1691
31. Methenamine Hippurate [vandf]
32. Mfcd00072147
33. S9466
34. Methenamine Hippurate [mart.]
35. Akos037645132
36. Methenamine Hippurate [usp-rs]
37. Methenamine Hippurate [who-dd]
38. N-benzoylglycine, Compound With 1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane (1:1)
39. Methenamine Hippurate (200 Mg)
40. As-57463
41. Methenamine Hippurate [orange Book]
42. Methenamine Hippurate [usp Impurity]
43. Cs-0013675
44. Ft-0671059
45. Methenamine Hippurate [usp Monograph]
46. D00855
47. D81437
48. 714m738
49. Q27283414
50. 1,3,5,7-tetraazatricyclo[3.3.1.1(3),?]decane; 2-(phenylformamido)acetic Acid
51. N-[hydroxy(phenyl)methylidene]glycine--1,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane (1/1)
Molecular Weight | 319.36 g/mol |
---|---|
Molecular Formula | C15H21N5O3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 319.16443955 g/mol |
Monoisotopic Mass | 319.16443955 g/mol |
Topological Polar Surface Area | 79.4 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 282 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Hiprex |
Drug Label | Each yellow capsule-shaped tablet contains 1 g Methenamine Hippurate which is the Hippuric Acid Salt of Methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients. FD&C Yellow No. 5 (tartrazine, see PRECAUTIONS), Magnesium S. |
Active Ingredient | Methenamine hippurate |
Dosage Form | Tablet |
Route | Oral |
Strength | 1gm |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 4 | |
---|---|
Drug Name | Methenamine hippurate |
PubMed Health | Methenamine (By mouth) |
Drug Classes | Antiseptic |
Drug Label | Methenamine Hippurate Tablets are a urinary tract antiseptic drug. Each white, scored tablet contains methenamine hippurate 1g (see HOW SUPPLIED). Methenamine Hippurate Tablets also contain: magnesium stearate, povidone and saccharin sodium. Chemical... |
Active Ingredient | Methenamine hippurate |
Dosage Form | Tablet |
Route | Oral |
Strength | 1gm |
Market Status | Prescription |
Company | Corepharma |
3 of 4 | |
---|---|
Drug Name | Hiprex |
Drug Label | Each yellow capsule-shaped tablet contains 1 g Methenamine Hippurate which is the Hippuric Acid Salt of Methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients. FD&C Yellow No. 5 (tartrazine, see PRECAUTIONS), Magnesium S. |
Active Ingredient | Methenamine hippurate |
Dosage Form | Tablet |
Route | Oral |
Strength | 1gm |
Market Status | Prescription |
Company | Sanofi Aventis Us |
4 of 4 | |
---|---|
Drug Name | Methenamine hippurate |
PubMed Health | Methenamine (By mouth) |
Drug Classes | Antiseptic |
Drug Label | Methenamine Hippurate Tablets are a urinary tract antiseptic drug. Each white, scored tablet contains methenamine hippurate 1g (see HOW SUPPLIED). Methenamine Hippurate Tablets also contain: magnesium stearate, povidone and saccharin sodium. Chemical... |
Active Ingredient | Methenamine hippurate |
Dosage Form | Tablet |
Route | Oral |
Strength | 1gm |
Market Status | Prescription |
Company | Corepharma |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Anti-Infective Agents, Urinary
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-07-23
Pay. Date : 2024-07-08
DMF Number : 40057
Submission : 2024-07-04
Status : Active
Type : II
NDC Package Code : 58159-105
Start Marketing Date : 2024-10-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-27
Pay. Date : 2014-03-28
DMF Number : 28120
Submission : 2014-04-04
Status : Active
Type : II
NDC Package Code : 65319-1098
Start Marketing Date : 2019-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-11-20
Pay. Date : 2017-10-16
DMF Number : 31988
Submission : 2017-10-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16801
Submission : 2003-08-08
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-11-24
Pay. Date : 2021-09-24
DMF Number : 34680
Submission : 2020-10-10
Status : Active
Type : II
Date of Issue : 2022-08-29
Valid Till : 2025-07-26
Written Confirmation Number : WC-0180
Address of the Firm :
NDC Package Code : 58793-008
Start Marketing Date : 2016-12-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-08
Pay. Date : 2013-04-15
DMF Number : 27021
Submission : 2013-04-09
Status : Active
Type : II
NDC Package Code : 65862-808
Start Marketing Date : 2023-12-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7333
Submission : 1988-02-08
Status : Active
Type : II
NDC Package Code : 17381-305
Start Marketing Date : 2010-04-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29058
Submission : 2015-05-13
Status : Inactive
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4949
Submission : 1983-05-23
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2024-07-23
Pay. Date : 2024-07-08
DMF Number : 40057
Submission : 2024-07-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-10-27
Pay. Date : 2014-03-28
DMF Number : 28120
Submission : 2014-04-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7100
Submission : 1987-08-04
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-08
Pay. Date : 2013-04-15
DMF Number : 27021
Submission : 2013-04-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16801
Submission : 2003-08-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-11-20
Pay. Date : 2017-10-16
DMF Number : 31988
Submission : 2017-10-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29058
Submission : 2015-05-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7333
Submission : 1988-02-08
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5018
Submission : 1983-07-29
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4949
Submission : 1983-05-23
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Sweden
Brand Name : Hiprex
Dosage Form : ORAL POWDER IN SACHET
Dosage Strength : 1 G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Hiprex
Dosage Form : TABLET
Dosage Strength : 1 G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Hiprex
Dosage Form : Antic-calc Tablet
Dosage Strength : 1 g
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Hiprex
Dosage Form : Antic-calc Tablet
Dosage Strength : 1 g
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Hiprex
Dosage Form : Powder in dose bag
Dosage Strength : 1 g
Packaging : Dose Bag
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Australia
Brand Name : Uramet
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Uramet
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Hiprex
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Hiprex
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Dosage Form : Capsule
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Dosage Form : Capsule
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Pharmacopoeia Ref : Ph. Eur., USP: Povidone; JPE: ...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Controlled & Modified Release
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Dosage Form : Tablet
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Binder for peroxide sensitive drugs in solid oral dosage forms. Drug solubilizer with low peroxide in transdermal patches.
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Tablet binding, thickener, stabilizers of suspensions, reduces sedimentation, crystallization inhibition.
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for tablets.
Dosage Form : Tablet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for lozenges, chewables and effervescent tablets.
Pharmacopoeia Ref : Ph. Eur., USP/NF and J.P
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Oral
Application : Thickeners and Stabilizers
Excipient Details : Adsorbent, Moisture Protection, Stabilization of API
Pharmacopoeia Ref : USP-NF, JP, EP
Technical Specs : Also Available as FUJISIL-F
Ingredient(s) : Silicon Dioxide
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : USP-NF, EP, BP, IP, JP, FCC
Technical Specs : PVP K-K-30/ K-17/ K19/ K25/ K90
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Methenamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Methenamine, including repackagers and relabelers. The FDA regulates Methenamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Methenamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Methenamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Methenamine supplier is an individual or a company that provides Methenamine active pharmaceutical ingredient (API) or Methenamine finished formulations upon request. The Methenamine suppliers may include Methenamine API manufacturers, exporters, distributors and traders.
click here to find a list of Methenamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Methenamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Methenamine active pharmaceutical ingredient (API) in detail. Different forms of Methenamine DMFs exist exist since differing nations have different regulations, such as Methenamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Methenamine DMF submitted to regulatory agencies in the US is known as a USDMF. Methenamine USDMF includes data on Methenamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Methenamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Methenamine suppliers with USDMF on PharmaCompass.
A Methenamine written confirmation (Methenamine WC) is an official document issued by a regulatory agency to a Methenamine manufacturer, verifying that the manufacturing facility of a Methenamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Methenamine APIs or Methenamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Methenamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Methenamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Methenamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Methenamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Methenamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Methenamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Methenamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Methenamine suppliers with NDC on PharmaCompass.
Methenamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Methenamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Methenamine GMP manufacturer or Methenamine GMP API supplier for your needs.
A Methenamine CoA (Certificate of Analysis) is a formal document that attests to Methenamine's compliance with Methenamine specifications and serves as a tool for batch-level quality control.
Methenamine CoA mostly includes findings from lab analyses of a specific batch. For each Methenamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Methenamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Methenamine EP), Methenamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Methenamine USP).
LOOKING FOR A SUPPLIER?